ARAngel Jonathan Ruiz-Moreno

Angel Jonathan Ruiz-Moreno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angel Jonathan Ruiz-Moreno has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Microbiome-wide PheWAS links gut microbial SNVs to health and exposures

    by Daoming Wang, Archontis Goumagias, Sergio Andreu-Sánchez, Haoran Peng, Angel J. Ruiz-Moreno, Daria V. Zhernakova, Tim Krempel, Yue Zhang, Jiafei Wu, Alexander Kurilshikov, et al.

  • Open Access

    Pregnancy and Early-Life Gut Virome in the Lifelines NEXT cohort: Origin, Persistence, Influencing Factors and Health Implications

    by Asier Fernández-Pato, Anastasia Gulyaeva, Nataliia Kuzub, Trishla Sinha, Siobhan Brushett, Johanne E. Spreckels, Milla Brandao Gois, Archontis Goumagias, Angel Ruiz-Moreno, Antonio Pedro Camargo, et al.

    The human gut virome is a key modulator of gut microbial ecology and function, yet its role in early gut ecosystem development remains poorly understood. Here, we profiled the DNA virome from 4,523 fecal and 91 breastmilk metagenomes from 714 mother–infant pairs in the Dutch birth cohort Lifelines NEXT. This analysis generated a catalog of 31,205 unique vOTUs, with 31,019 detected in fecal and 248 in breastmilk samples, including 16,540 not previously reported in other databases. We find that the maternal virome is largely stable, in contrast to the infant virome’s rapid diversification over time. We also identify delivery and feeding modes as major drivers of infant virome developmental trajectories, with additional influences of maternal parity, infections during pregnancy, socioeconomic factors, gestational age and infant birth weight. Notably, increased viral diversity was associated with the infant developing a food allergy. Strain-level virome profiling confirmed the maternal gut as the primary source of viruses for the infant gut, with increased sharing rates in vaginally delivered infants and with breastmilk as a secondary reservoir. We demonstrate that temperate phages frequently co-transmit with their bacterial hosts and identify multiple protein families associated with anti-defense functions enriched among maternally shared viruses. Finally, we show that DNA adenine N6-methyltransferase hin1523 , together with widely active diversity-generating retroelements, promote long-term viral persistence in the infant and maternal gut. Together, these findings establish the origin, dynamics and modulating factors of the infant gut virome, along with the genetic strategies supporting its persistence in the gut ecosystem.

  • Open Access

    MicrobeRX: a tool for enzymatic-reaction-based metabolite prediction in the gut microbiome

    by Angel J. Ruiz-Moreno, Ángela Del Castillo-Izquierdo, Isabel Tamargo-Rubio, Jingyuan Fu

    Background: The gut microbiome functions as a metabolic organ, producing numerous enzymes that influence host health; however, their substrates and metabolites remain largely unknown. Results: We present MicrobeRX, an enzyme-based metabolite prediction tool that employs 5487 human reactions and 4030 unique microbial reactions from 6286 genome-scale models, as well as 3650 drug metabolic reactions from the DrugBank database (v.5.1.12). MicrobeRX includes additional analysis modules for metabolite visualization and enzymatic and taxonomic analyses. When we applied MicrobeRX to 1083 orally administered drugs that have been approved in at least one jurisdiction at some point in time (DrugBank), it predicted metabolites with physicochemical properties and structures similar to metabolites found in biosamples (from MiMeDB). It also outperformed another existing metabolite prediction tool (BioTransformer 3.0) in terms of predictive potential, molecular diversity, reduction of redundant predictions, and enzyme annotation. Conclusions: Our analysis revealed both unique and overlapping metabolic capabilities in human and microbial metabolism and chemo- and taxa-specific microbial biotransformations. MicrobeRX bridges the genomic and chemical spaces of the gut microbiome, making it a valuable tool for unlocking the chemical potential of the gut microbiome in human health, the food and pharmaceutical industries, and environmental safety.


  • Open Access

    Microbiome-wide PheWAS links gut microbial SNVs to human health and exposures

    by Jingyuan Fu, Daoming Wang, Sergio Andreu-Sánchez, Haoran Peng, Angel Ruiz-Moreno, Daria Zhernakova, Alexander Kurilshikov, Ranko Gacesa, Godfrey Temba, Vesla Kullaya, et al.

    The importance of the gut microbiome in human health has been widely recognized, with alterations in species abundances now reported for many different diseases. In recent years, observations of within-species genetic diversity and strain-level functional differences have urged the field to transition to analyzing microbes at the genetic level, taking advantage of genetic variants in the metagenome to pinpoint relevant genes and pathways. Here, we conducted a phenome-wide association study (PheWAS) of 12.7 million gut microbial single nucleotide variants (SNVs) with 244 host health phenotypes and environmental exposures in 10,781 individuals from six independent cohorts from Europe and Africa. We found 3,018 associations supported by at least two cohorts for 105 host factors, including age, sex and cardiovascular and metabolic parameters. Moreover, we found 34,927 significant associations in single-cohort analyses where SNV–phenotype pairs were only available for one cohort. All identified associations are detailed in an online catalog (https://fulab.web.rug.nl/SNV-MWAS/). The associated microbial SNVs inform mechanistic hypotheses about microbial functionality in human health and provide insights into microbial adaptation and evolution in response to changes in the environment and host physiology. For example, we identified 718 age-associated gut microbial SNVs across multiple cohorts and used these microbial SNVs to accurately predict host age. We also identified SNVs in microbial genes associated with lipid concentrations and BMI, including SNVs in the isoleucine-tRNA synthetase gene of Clostridium phoceensis and an α-Melanocyte-stimulating hormone-mimicking clpB gene of Alistipes ihumii. Mediation analysis provided evidence that microbial genetic variations may be under selection enforced by environmental factors, but also that they mediate the effects on the host, e.g. the isoleucyl-tRNA synthetase gene of C. phoceensis mediated dietary effects on four phenotypes. Overall, this study identifies new biological connections between human host and microbial genetic variants, exposing the functional layer of gut microbiome data hidden at base pair resolution and revealing microbial adaptation and evolution in relation to host lifestyle and physiology.


  • Open Access

    Small‐Molecule Allosteric Inhibitors of Human Aspartate Transcarbamoylase Suppress Proliferation of Bone Osteosarcoma Epithelial Cells

    by Chao Wang, Bidong Zhang, Yingying Cong, Xiaochen Du, Siyao Chen, Lidia Visser, Angel J. Ruiz‐Moreno, Lili Zhang, Fulvio Reggiori, Alexander S. S. Dömling, et al.

    Aspartate transcarbamoylase (ATC) is the first committed step in de novo pyrimidine biosynthesis in eukaryotes and plants. A potent transition state analog of human ATCase (PALA) has previously been assessed in clinical trials for the treatment of cancer, but was ultimately unsuccessful. Additionally, inhibition of this pathway has been proposed to be a target to suppress cell proliferation in E. coli, the malarial parasite and tuberculosis. In this manuscript we screened a 70‐member library of ATC inhibitors developed against the malarial and tubercular ATCases for inhibitors of the human ATC. Four compounds showed low nanomolar inhibition (IC50 30–120 nM) in an in vitro activity assay. These compounds significantly outperform PALA, which has a triphasic inhibition response under identical conditions, in which significant activity remains at PALA concentrations above 10 μM. Evidence for a druggable allosteric pocket in human ATC is provided by both in vitro enzyme kinetic, homology modeling and in silico docking. These compounds also suppress the proliferation of U2OS osteoblastoma cells by promoting cell cycle arrest in G0/G1 phase. This report provides the first evidence for an allosteric pocket in human ATC, which greatly enhances its druggability and demonstrates the potential of this series in cancer therapy.


  • Open Access

    Consensus Pharmacophore Strategy For Identifying Novel SARS-Cov-2 Mpro Inhibitors from Large Chemical Libraries

    by Angel J. Ruiz-Moreno, Raziel Cedillo-González, Luis Cordova-Bahena, Zhiqiang An, José L. Medina-Franco, Marco A. Velasco-Velázquez

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main Protease (Mpro) is an enzyme that cleaves viral polyproteins translated from the viral genome and is critical for viral replication. Mpro is a target for anti-SARS-CoV-2 drug development, and multiple Mpro crystals complexed with competitive inhibitors have been reported. In this study, we aimed to develop an Mpro consensus pharmacophore as a tool to expand the search for inhibitors. We generated a consensus model by aligning and summarizing pharmacophoric points from 152 bioactive conformers of SARS-CoV-2 Mpro inhibitors. Validation against a library of conformers from a subset of ligands showed that our model retrieved poses that reproduced the crystal-binding mode in 77% of the cases. Using models derived from a consensus pharmacophore, we screened >340 million compounds. Pharmacophore-matching and chemoinformatics analyses identified new potential Mpro inhibitors. The candidate compounds were chemically dissimilar to the reference set, and among them, demonstrating the relevance of our model. We evaluated the effect of 16 candidates on Mpro enzymatic activity finding that seven have inhibitory activity. Three compounds (1, 4, and 5) had IC50 values in the midmicromolar range. The Mpro consensus pharmacophore reported herein can be used to identify compounds with improved activity and novel chemical scaffolds against Mpro. The method developed for its generation is provided as an open-access code (https://github.com/AngelRuizMoreno/ConcensusPharmacophore) and can be applied to other pharmacological targets.


  • Top Cited Papers
    Open Access

    Host genetic regulation of human gut microbial structural variation

    by Daria V. Zhernakova, Daoming Wang, Lei Liu, Sergio Andreu-Sánchez, Yue Zhang, Angel J. Ruiz-Moreno, Haoran Peng, Niels Plomp, Ángela Del Castillo-Izquierdo, Ranko Gacesa, et al.

    Although the impact of host genetics on gut microbial diversity and the abundance of specific taxa is well established1–6, little is known about how host genetics regulates the genetic diversity of gut microorganisms. Here we conducted a meta-analysis of associations between human genetic variation and gut microbial structural variation in 9,015 individuals from four Dutch cohorts. Strikingly, the presence rate of a structural variation segment in Faecalibacterium prausnitzii that harbours an N-acetylgalactosamine (GalNAc) utilization gene cluster is higher in individuals who secrete the type A oligosaccharide antigen terminating in GalNAc, a feature that is jointly determined by human ABO and FUT2 genotypes, and we could replicate this association in a Tanzanian cohort. In vitro experiments demonstrated that GalNAc can be used as the sole carbohydrate source for F. prausnitzii strains that carry the GalNAc-metabolizing pathway. Further in silico and in vitro studies demonstrated that other ABO-associated species can also utilize GalNAc, particularly Collinsella aerofaciens. The GalNAc utilization genes are also associated with the host’s cardiometabolic health, particularly in individuals with mucosal A-antigen. Together, the findings of our study demonstrate that genetic associations across the human genome and bacterial metagenome can provide functional insights into the reciprocal host–microbiome relationship.


  • Open Access

    Identification of hotspots in synthetic peptide inhibitors of the FOXO4:p53 interaction

    by Ran Zhang, Kai Gao, Afsaneh Sadremomtaz, Angel J. Ruiz-Moreno, Alessandra Monti, Zayana M. Al-Dahmani, Benjamin B. Gyau, Nunzianna Doti, Matthew R. Groves

    AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.


  • Open Access

    Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening

    by Luis Córdova-Bahena, Axel A. Sánchez-Álvarez, Angel J. Ruiz-Moreno, Marco A. Velasco-Velázquez

    CK1ε is a key regulator of WNT/β-catenin and other pathways that are linked to tumor progression; thus, CK1ε is considered a target for the development of antineoplastic therapies. In this study, we performed a virtual screening to search for potential CK1ε inhibitors. First, we characterized the dynamic noncovalent interactions profiles for a set of reported CK1ε inhibitors to generate a pharmacophore model, which was used to identify new potential inhibitors among FDA-approved drugs. We found that etravirine and abacavir, two drugs that are approved for HIV infections, can be repurposed as CK1ε inhibitors. The interaction of these drugs with CK1ε was further examined by molecular docking and molecular dynamics. Etravirine and abacavir formed stable complexes with the target, emulating the binding behavior of known inhibitors. However, only etravirine showed high theoretical binding affinity to CK1ε. Our findings provide a new pharmacophore for targeting CK1ε and implicate etravirine as a CK1ε inhibitor and antineoplastic agent.


  • Open Access

    In Silico Design and Selection of New Tetrahydroisoquinoline-Based CD44 Antagonist Candidates

    by Angel J. Ruiz-Moreno, Atilio Reyes-Romero, Alexander Dömling, Marco A. Velasco-Velázquez

    CD44 promotes metastasis, chemoresistance, and stemness in different types of cancer and is a target for the development of new anti-cancer therapies. All CD44 isoforms share a common N-terminal domain that binds to hyaluronic acid (HA). Herein, we used a computational approach to design new potential CD44 antagonists and evaluate their target-binding ability. By analyzing 30 crystal structures of the HA-binding domain (CD44HAbd), we characterized a subdomain that binds to 1,2,3,4-tetrahydroisoquinoline (THQ)-containing compounds and is adjacent to residues essential for HA interaction. By computational combinatorial chemistry (CCC), we designed 168,190 molecules and compared their conformers to a pharmacophore containing the key features of the crystallographic THQ binding mode. Approximately 0.01% of the compounds matched the pharmacophore and were analyzed by computational docking and molecular dynamics (MD). We identified two compounds, Can125 and Can159, that bound to human CD44HAbd (hCD44HAbd) in explicit-solvent MD simulations and therefore may elicit CD44 blockage. These compounds can be easily synthesized by multicomponent reactions for activity testing and their binding mode, reported here, could be helpful in the design of more potent CD44 antagonists.